Fondaparinux Sodium Injection, Solution
Product Images NDC 55150-232

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Fondaparinux Sodium (NDC 55150-232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Fondaparinux Fig1)

An instructional diagram showing two gloved hands pulling apart a two-part prefilled syringe or injection device with arrows indicating separation direction. It demonstrates how to separate the syringe parts before subcutaneous injection, relevant for Fondaparinux Sodium injection administration.*

FDA Label Image

Figure B. (Fondaparinux Fig10)

An instructional illustration showing two hands holding a syringe. The left hand holds a small cap, seemingly being removed or placed on the syringe's needle, indicated by two black arrows pointing in opposite directions between the hands.*

FDA Label Image

Figure C. (Fondaparinux Fig11)

Black and white photograph showing a person demonstrating self-administration of a subcutaneous injection into the abdominal area. The person's hand is pressing on the injection site, near the lower abdomen, indicating a step in the injection process for subcutaneous administration.*

FDA Label Image

Figure D. (Fondaparinux Fig12)

An instructional photograph showing a person preparing to administer a subcutaneous injection with a syringe, demonstrating the proper technique of pinching the skin around the abdomen.*

FDA Label Image

Figure E. (Fondaparinux Fig13)

A black-and-white instructional illustration showing a person preparing to administer a subcutaneous injection in the abdominal area. A syringe is positioned at the skin with an arrow indicating the injection site, demonstrating the proper technique for subcutaneous delivery of the medication.*

FDA Label Image

Figure F. (Fondaparinux Fig14)

An instructional black and white photograph showing a person administering a subcutaneous injection in the abdominal area. The image highlights the use of a syringe with a needle being inserted into the skin, indicated by an arrow pointing to the injection site. The hands are positioned to hold the syringe and pinch the skin appropriately for injection.*

FDA Label Image

Figure G. (Fondaparinux Fig15)

Illustration showing a hand holding a prefilled syringe containing an injection solution. An arrow points to the syringe plunger, indicating a step or action involving pressing or pushing the plunger.*

FDA Label Image

Package Label-principal Display Panel (2.5 mg per 0.5 mL)

Label for Fondaparinux Sodium Injection, USP with a strength of 2.5 mg per 0.5 mL. The label includes NDC 55150-230-00, distributor information for AuroMedics Pharma LLC in Windsor, NJ, and indicates the product is made in India. It is Rx only and includes a QR code and barcode.*

FDA Label Image

Package Label-principal Display Panel (2.5 mg per 0.5 mL)

Packaging label for Fondaparinux Sodium Injection, USP, 2.5 mg per 0.5 mL, in a subcutaneous injection solution form. The label indicates single-dose prefilled syringes, 2 x 0.5 mL per package. It features the brand name Fondaparinux with dosage strength prominently displayed. Distributed by AuroMedics Pharma LLC and includes a note for pharmacists to dispense the patient information leaflet. The product is made in India.*

FDA Label Image

Package Label-principal Display Panel (2.5 mg per 0.5 mL)

Packaging label for Fondaparinux Sodium Injection, USP 2.5 mg per 0.5 mL, single-dose prefilled syringes. The label states subcutaneous injection use, with 10 x 0.5 mL syringes per carton. Distributed by AuroMedics Pharma LLC, the label highlights the product is sterile, preservative-free, and includes storage instructions and contents details. The manufacturer is indicated as Eugia US LLC.*

FDA Label Image

Package Label-principal Display Panel (5 mg per 0.4 mL)

Label for Fondaparinux Sodium Injection USP, 5 mg per 0.4 mL solution for injection. The label indicates Rx only, NDC 55150-231-00, distributed by AuroMedics Pharma LLC, E. Windsor, NJ, made in India. The label includes a QR code, batch, and expiration information areas.*

FDA Label Image

Figure 2 (Fondaparinux Fig2)

A black and white instructional image showing a gloved hand administering a subcutaneous injection into the abdomen of a patient. The image highlights the correct injection site and technique for the administration of fondaparinux sodium injection solution.*

FDA Label Image

Package Label-principal Display Panel (5 mg per 0.4 mL)

Box packaging label for Fondaparinux Sodium Injection, USP 5 mg per 0.4 mL. The carton contains 2 single-dose prefilled syringes with automatic needle protection system for subcutaneous injection. Distributed by AuroMedics Pharma LLC. The label includes NDC 55150-231-02 and instructions for pharmacists to dispense with patient information leaflet. Made in India.*

FDA Label Image

Package Label-principal Display Panel (5 mg per 0.4 mL)

Carton label for Fondaparinux Sodium Injection, USP 5 mg per 0.4 mL, presented as single-dose prefilled syringes for subcutaneous injection. The label includes dosage strength, product form, and container size of 10 x 0.4 mL prefilled syringes. It lists the labeler as Auromedics Pharma LLC, with manufacturing information stating "Made in India." Storage, contents, and usage notes are also visible.*

FDA Label Image

Package Label-principal Display Panel (7.5 mg per 0.6 mL)

Label for Fondaparinux Sodium Injection, USP 7.5 mg per 0.6 mL, a subcutaneous injection solution. The label includes NDC 55150-232-00 and states distribution by AuroMedics Pharma LLC, E. Windsor, NJ, indicating it is made in India. Batch and expiration date areas are present but blank.*

FDA Label Image

Package Label-principal Display Panel (7.5 mg per 0.6 mL)

Packaging label for Fondaparinux Sodium Injection, USP 7.5 mg per 0.6 mL, a single-dose, prefilled syringe solution for subcutaneous injection. The carton contains 2 x 0.6 mL syringes and includes a note for pharmacists to dispense with patient information leaflet. Distributed by AuroMedics Pharma LLC, made in India.*

FDA Label Image

Package Label-principal Display Panel (7.5 mg per 0.6 mL)

Carton label for Fondaparinux Sodium Injection, USP 7.5 mg per 0.6 mL, a single-dose prefilled syringe solution for subcutaneous injection. The label includes dosing, storage, and content information, manufacturer details (Auromedics Pharma LLC), and instructions for pharmacists. Package contains ten 0.6 mL syringes with automatic needle protection system.*

FDA Label Image

Package Label-principal Display Panel (10 mg per 0.8 mL)

Label for Fondaparinux Sodium Injection, USP showing a strength of 10 mg per 0.8 mL. The label includes the NDC 55150-233-00, indicates Rx only status, and lists AuroMedics Pharma LLC as the distributor. It also notes the product is made in India and provides spaces for batch and expiration information.*

FDA Label Image

Package Label-principal Display Panel (10 mg per 0.8 mL)

Packaging label for Fondaparinux Sodium Injection, USP 10 mg per 0.8 mL, an injection solution in single-dose prefilled syringes. The box contains 2 x 0.8 mL syringes for subcutaneous use. It includes dosing information, distribution by AuroMedics Pharma LLC, and is made in India. The label also mentions an automatic needle protection system.*

FDA Label Image

Package Label-principal Display Panel (10 mg per 0.8 mL)

Packaging label for Fondaparinux Sodium Injection, USP 10 mg per 0.8 mL single-dose prefilled syringes. The label indicates the product is sterile, preservative-free, and intended for subcutaneous injection with an automatic needle protection system. It is distributed by AuroMedics Pharma LLC and made in India. The package contains 10 prefilled syringes of 0.8 mL each.*

FDA Label Image

Package Label-principal Display Panel (2.5 mg per 0.5 mL)

Label for Fondaparinux Sodium Injection, USP 2.5 mg per 0.5 mL in a single-dose, prefilled syringe with an automatic needle protection system. The label indicates it is for subcutaneous injection, distributed by AuroMedics Pharma LLC, and sterile preservative-free. Storage instructions and manufacturer details are included, along with a barcode and NDC 55150-230-00.*

FDA Label Image

Package Label-principal Display Panel (5 mg per 0.4 mL)

Label for Fondaparinux Sodium Injection, USP 5 mg per 0.4 mL single-dose prefilled syringe with automatic needle protection system for subcutaneous injection. The label states prescription use, barcode, storage instructions, and distributor details for AuroMedics Pharma LLC. The product is sterile and preservative-free.*

FDA Label Image

Figure 3 (Fondaparinux Fig3)

Instructional black-and-white photo illustrating the subcutaneous injection technique for Fondaparinux Sodium. The image shows gloved hands administering the injection into the abdominal area, indicated by an arrow pointing to the injection site.*

FDA Label Image

Package Label-principal Display Panel – 7.5 mg Per 0.6 mL (Prefilled Syringe Blister Pack Label)

Label for Fondaparinux Sodium Injection USP 7.5 mg per 0.6 mL single-dose prefilled syringe. The label indicates it is for subcutaneous injection and includes patient information instructions. Distributed by AuroMedics Pharma LLC, the syringe contains 7.5 mg fondaparinux sodium in 0.6 mL.*

FDA Label Image

Package Label-principal Display Panel – 10 mg Per 0.8 mL (Prefilled Syringe Blister Pack Label)

Label for Fondaparinux Sodium Injection, USP 10 mg per 0.8 mL in a single-dose prefilled syringe with automatic needle protection, for subcutaneous injection. The label shows the dosage strength, use instructions, storage conditions, distributor AuroMedics Pharma LLC, and barcode. It indicates the product is sterile and preservative-free.*

FDA Label Image

Figure 4 (Fondaparinux Fig4)

An instructional illustration showing a gloved hand holding a pre-filled injection syringe, positioned with the needle facing downward. An arrow points toward the syringe barrel, indicating a specific action related to the injection process.*

FDA Label Image

Figure 5 (Fondaparinux Fig5)

An instructional illustration showing a gloved hand holding a syringe and disposing of it into a container labeled with a biohazard symbol, indicating proper syringe disposal procedure.*

FDA Label Image

Figure 6 (Fondaparinux Fig6)

An instructional diagram showing a subcutaneous injection syringe of Fondaparinux Sodium. The image includes numbered labels pointing to parts of the syringe: (1) the needle cap, (2) the plunger, (3) the finger grip, and (4) the syringe barrel containing the solution dose. The syringe is intended for subcutaneous administration.*

FDA Label Image

Syringe Before Use (Fondaparinux Fig7)

An instructional diagram of a pre-filled syringe for Fondaparinux Sodium injection, illustrating key parts such as the plunger, barrel, and needle, designed for subcutaneous administration. The syringe contains solution for precise dosing of Fondaparinux Sodium.*

FDA Label Image

Syringe After Use (Fondaparinux Fig8)

An instructional diagram showing a prefilled syringe of Fondaparinux Sodium injection solution for subcutaneous use. The syringe is labeled with numbered callouts indicating specific parts of the device, including the plunger, needle, and protective components. The image visually supports proper syringe handling or administration steps.*

FDA Label Image

Figure A. (Fondaparinux Fig9)

FDA Label Image

Fondaparinux Sodium Chemical Structure (Fondaparinux Str)

Chemical structure of fondaparinux sodium showing a complex sequence of sugar molecules with multiple sulfate (OSO3Na) and sodium carboxylate (COONa) groups, consistent with its identity as a synthetic pentasaccharide anticoagulant.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.